{"id":"anti-il6","safety":{"commonSideEffects":[{"rate":"30%","effect":"Neutropenia"},{"rate":"20%","effect":"Thrombocytopenia"},{"rate":"15%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Anti-IL6 drugs work by binding to the IL-6 receptor, preventing IL-6 from interacting with its receptor and thereby reducing inflammation.","oneSentence":"IL-6 receptor antagonist","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:52:54.299Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Multiple myeloma"}]},"trialDetails":[{"nctId":"NCT04729959","phase":"PHASE2","title":"Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-11","conditions":"Diffuse Astrocytoma, IDH-Wildtype, Recurrent Glioblastoma","enrollment":59},{"nctId":"NCT07276282","phase":"PHASE3","title":"Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction","status":"RECRUITING","sponsor":"ECRI bv","startDate":"2025-12-19","conditions":"Coronary Artery Disease, Acute Myocardial Infarction (AMI), Coronary Atherosclerosis of Native Coronary Artery","enrollment":332},{"nctId":"NCT06793085","phase":"","title":"Pro- and Anti-inflammatory Cytokines in PCOS","status":"RECRUITING","sponsor":"Jagiellonian University","startDate":"2025-01-20","conditions":"Reproductive Age, PCOS (Polycystic Ovary Syndrome)","enrollment":100},{"nctId":"NCT04940299","phase":"PHASE2","title":"Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-09-23","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Bladder Carcinoma","enrollment":35},{"nctId":"NCT07429773","phase":"NA","title":"Identify a Specific Immune Profile in Patients With Chronic Pelvic Pain Resistant to First-line Treatments by Measuring Th1, Th2, Th17, and Treg Cytokines Produced After Non-specific Functional Cell Stimulation - ImmunoCPP","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2026-04","conditions":"Endometriosis, Chronic Pelvic Pain Syndrome","enrollment":120},{"nctId":"NCT06362759","phase":"PHASE2","title":"A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP","status":"COMPLETED","sponsor":"Tourmaline Bio, Inc.","startDate":"2024-05-15","conditions":"Chronic Kidney Diseases, Chronic Kidney Insufficiency, Chronic Renal Diseases","enrollment":143},{"nctId":"NCT05391750","phase":"PHASE1","title":"Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2022-10-19","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":7},{"nctId":"NCT03761108","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2019-01-23","conditions":"Multiple Myeloma","enrollment":387},{"nctId":"NCT05305066","phase":"NA","title":"Stand UP to Rheumatoid Arthritis (SUPRA)","status":"RECRUITING","sponsor":"Marie Hudson, MD","startDate":"2023-02-01","conditions":"Rheumatoid Arthritis","enrollment":75},{"nctId":"NCT07377058","phase":"NA","title":"RCT of Tocilizumab for Anti-MDA5+DM","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-11-01","conditions":"Dermatomyositis","enrollment":110},{"nctId":"NCT06470971","phase":"PHASE2","title":"Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial","status":"RECRUITING","sponsor":"Yuanquan Yang","startDate":"2024-07-09","conditions":"Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm","enrollment":40},{"nctId":"NCT07349472","phase":"PHASE2","title":"Pentoxifylline in Patients With Ulcerative Colitis","status":"NOT_YET_RECRUITING","sponsor":"Ihab Elsayed Hassan","startDate":"2026-01-20","conditions":"Inflammatory Bowel Diseases","enrollment":60},{"nctId":"NCT07319650","phase":"NA","title":"Efficacy Of Platelet Rich Fibrin (PRF) In Neurosensory Disturbance Among Patients With Mandibular Body Fractures","status":"NOT_YET_RECRUITING","sponsor":"University of Health Sciences Lahore","startDate":"2026-01","conditions":"Neurosensory Disturbance, Mandibular Body Fractures","enrollment":40},{"nctId":"NCT04779957","phase":"PHASE2","title":"Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2021-10-01","conditions":"Kidney Transplantation, Graft Failure","enrollment":18},{"nctId":"NCT03926117","phase":"PHASE2","title":"Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-06-03","conditions":"Chronic Kidney Diseases, Inflammation","enrollment":264},{"nctId":"NCT05018299","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of FB704A in Adult With Severe Asthma","status":"RECRUITING","sponsor":"Oneness Biotech Co., Ltd.","startDate":"2021-09-30","conditions":"Severe Asthma","enrollment":20},{"nctId":"NCT06263244","phase":"PHASE3","title":"Specifying the Anti-inflammatory Effects of Ziltivekimab","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2024-05-03","conditions":"Atherosclerosis, Inflammation","enrollment":40},{"nctId":"NCT06703593","phase":"PHASE2","title":"Prevention of Doxorubicin-induced Cardiotoxicity in Breast Cancer Patients","status":"COMPLETED","sponsor":"British University In Egypt","startDate":"2023-10-01","conditions":"Breast Cancer Female","enrollment":80},{"nctId":"NCT04803370","phase":"NA","title":"Efficacy of Reinforcing Standard Therapy in COVID-19 Patients With Repeated Transfusion of Convalescent Plasma","status":"COMPLETED","sponsor":"Hospital Son Llatzer","startDate":"2020-07-08","conditions":"Covid19","enrollment":55},{"nctId":"NCT06737380","phase":"PHASE1","title":"UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients","status":"RECRUITING","sponsor":"LiveKidney.Bio","startDate":"2025-01-07","conditions":"SLE, Lupus, Systemic Lupus Erthematosus","enrollment":10},{"nctId":"NCT04007029","phase":"PHASE1","title":"Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-10-04","conditions":"CD19 Positive, CD20 Positive, Recurrent Chronic Lymphocytic Leukemia","enrollment":24},{"nctId":"NCT06545812","phase":"NA","title":"Immune Response During the Conservative and Minimal Invasive Treatment of Pain Caused by Lumbar Disc Herniation","status":"RECRUITING","sponsor":"Josip Juraj Strossmayer University of Osijek","startDate":"2024-09-02","conditions":"Intervertebral Disc Herniation, Back Pain, Analgesic Nephropathy","enrollment":128},{"nctId":"NCT05679570","phase":"PHASE2","title":"Satralizumab in the Treatment of Pulmonary Arterial Hypertension (SATISFY-JP Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"International University of Health and Welfare","startDate":"2022-07-12","conditions":"Pulmonary Arterial Hypertension","enrollment":20},{"nctId":"NCT07125664","phase":"PHASE2","title":"Intravenous Alpha-1 Antitrypsin for Hospitalized Patients With COPD Exacerbations (AECOPD Study)","status":"NOT_YET_RECRUITING","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2025-10-01","conditions":"Acute Exacerbation Chronic Obstructive Pulmonary Disease","enrollment":36},{"nctId":"NCT04191421","phase":"PHASE1, PHASE2","title":"Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Emory University","startDate":"2020-01-17","conditions":"Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8","enrollment":35},{"nctId":"NCT06726096","phase":"PHASE3","title":"Phase III Trial of VDJ001 In Patients With Moderate-to-severe Active Rheumatoid Arthritis","status":"ENROLLING_BY_INVITATION","sponsor":"Beijing VDJBio Co., LTD.","startDate":"2025-04-09","conditions":"Rheumatoid Arthritis (RA), Anti IL-6R","enrollment":615},{"nctId":"NCT05345522","phase":"PHASE2","title":"A Study of Anti-IL-6R mAb Injection in Patients With iMCD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing VDJBio Co., LTD.","startDate":"2022-04-18","conditions":"Idiopathic Multicentric Castleman's Disease","enrollment":25},{"nctId":"NCT05957107","phase":"PHASE2","title":"Phase II Trial of VDJ001 in Patients With Moderate-to-severe Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Beijing VDJBio Co., LTD.","startDate":"2022-05-26","conditions":"Rheumatoid Arthritis","enrollment":181},{"nctId":"NCT06884969","phase":"","title":"Late-onset Sepsis and Development","status":"COMPLETED","sponsor":"Nigde Omer Halisdemir University","startDate":"2025-03-19","conditions":"Sepsis Newborn, Motor Development, Sensory Integration Dysfunction","enrollment":57},{"nctId":"NCT04129931","phase":"PHASE2","title":"PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2019-12-19","conditions":"Asthma","enrollment":395},{"nctId":"NCT07014839","phase":"","title":"Post-Implantation Syndrome and Laboratory Markers Following EVAR and TEVAR","status":"COMPLETED","sponsor":"Ataturk University","startDate":"2018-01-01","conditions":"Postimplantation Syndrome, Endovascular Abdominal Aortic Aneurysm Repair (EVAR), Thoracic Endovascular Aortic Repair","enrollment":300},{"nctId":"NCT06987916","phase":"PHASE1, PHASE2","title":"Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma","status":"RECRUITING","sponsor":"Shanghai Tongji Hospital, Tongji University School of Medicine","startDate":"2025-04-22","conditions":"B Cell Lymphoma","enrollment":50},{"nctId":"NCT03380377","phase":"PHASE1, PHASE2","title":"Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant","status":"COMPLETED","sponsor":"Stanley Jordan, MD","startDate":"2018-02-21","conditions":"Antibody-mediated Rejection, Kidney Transplant; Complications, Transplant Glomerulopathy","enrollment":10},{"nctId":"NCT05842096","phase":"NA","title":"Subclinical Hypothyroidism and Chronic Inflammation in PCOS","status":"COMPLETED","sponsor":"Jagiellonian University","startDate":"2024-01-01","conditions":"PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, Subclinical hypothyroïdism, Hypothalamic-Pituitary-Gonadal Axis Dysfunction","enrollment":158},{"nctId":"NCT03380962","phase":"PHASE1, PHASE2","title":"Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stanley Jordan, MD","startDate":"2018-02-27","conditions":"Kidney Failure, Chronic, End-Stage Renal Disease, Transplant Glomerulopathy","enrollment":20},{"nctId":"NCT04370834","phase":"PHASE2","title":"Tocilizumab for Patients With Cancer and COVID-19 Disease","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2020-05-28","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Pneumonia","enrollment":1},{"nctId":"NCT05665725","phase":"PHASE1","title":"Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Timothy Voorhees","startDate":"2023-01-31","conditions":"Non-Hodgkin Lymphoma","enrollment":11},{"nctId":"NCT03770273","phase":"PHASE2","title":"Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-06-19","conditions":"Indolent Systemic Mastocytosis","enrollment":21},{"nctId":"NCT04066114","phase":"PHASE1, PHASE2","title":"Treg Modulation With CD28 and IL-6 Receptor Antagonists","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-11","conditions":"Living-Donor Kidney Transplant, Kidney Transplant Recipients","enrollment":24},{"nctId":"NCT04347798","phase":"","title":"IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2020-11-01","conditions":"Covid-19 Infection, Rheumatoid Arthritis, Psoriatic Arthritis","enrollment":773},{"nctId":"NCT01242488","phase":"PHASE2","title":"Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2010-11","conditions":"Rheumatoid Arthritis","enrollment":221},{"nctId":"NCT03098355","phase":"PHASE1, PHASE2","title":"Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies","status":"WITHDRAWN","sponsor":"Zhujiang Hospital","startDate":"2017-12-30","conditions":"B-Cell Leukemia, B-Cell Lymphoma","enrollment":""},{"nctId":"NCT05699785","phase":"NA","title":"Comparison of Inflammatory Markers and Incidence of Comorbidities in Patients on Antiretroviral Therapy With Second-generation Anti-integrase Drugs on Triple Versus Dual Therapy","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2023-02-16","conditions":"Hiv","enrollment":500},{"nctId":"NCT04348500","phase":"PHASE2","title":"Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19)","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2020-04-28","conditions":"COVID-19","enrollment":17},{"nctId":"NCT06231459","phase":"PHASE4","title":"Expression of Pro- and Anti-inflammatory Cytokines During Anti-PCSK9 in Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado","startDate":"2019-01-01","conditions":"Hypercholesterolemia, Familial","enrollment":20},{"nctId":"NCT06048224","phase":"PHASE3","title":"Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Zhejiang Hisun Pharmaceutical Co. Ltd.","startDate":"2020-12-28","conditions":"Moderate to Severe Active Rheumatoid Arthritis","enrollment":669},{"nctId":"NCT04321993","phase":"PHASE2","title":"Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients","status":"UNKNOWN","sponsor":"Lisa Barrett","startDate":"2020-04-17","conditions":"COVID-19","enrollment":363},{"nctId":"NCT06021574","phase":"PHASE1","title":"A First-in-human Study of a Novel Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody","status":"COMPLETED","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2019-06-28","conditions":"Healthy","enrollment":40},{"nctId":"NCT04756128","phase":"PHASE2","title":"Impact of Colchicine and Low-dose Naltrexone on COVID-19","status":"COMPLETED","sponsor":"HealthPartners Institute","startDate":"2021-01-25","conditions":"Covid19","enrollment":142},{"nctId":"NCT05696106","phase":"","title":"Risk of Incident IMID in Patients Treated With Biologics and Immunosuppressive Drugs for a Single IMID","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-04-02","conditions":"Inflammatory Disease","enrollment":750000},{"nctId":"NCT05800327","phase":"PHASE3","title":"A Two-Stage Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Various Doses of Levilimab When Administered Intravenously and Subcutaneously to Healthy Subjects and Subjects With Active Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biocad","startDate":"2022-12-07","conditions":"Rheumatoid Arthritis","enrollment":261},{"nctId":"NCT04330638","phase":"PHASE3","title":"Treatment of COVID-19 Patients With Anti-interleukin Drugs","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2020-04-03","conditions":"COVID-19","enrollment":342},{"nctId":"NCT03726749","phase":"PHASE4","title":"Tocilizumab Plus a Short Prednisone Taper for GCA","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2018-11-28","conditions":"Giant Cell Arteritis","enrollment":30},{"nctId":"NCT04404335","phase":"","title":"The Role of Anti-inflammatory Cytokines and Antimicrobial Peptide LL-37 Biomarkers in the Treatment of Periodontal Disease.","status":"COMPLETED","sponsor":"Universidad Rey Juan Carlos","startDate":"2021-05-17","conditions":"Periodontal Diseases, Periodontitis","enrollment":60},{"nctId":"NCT04333914","phase":"PHASE2","title":"Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection","status":"COMPLETED","sponsor":"Centre Leon Berard","startDate":"2020-04-15","conditions":"SARS-CoV-2 (COVID-19) Infection, Advanced or Metastatic Hematological or Solid Tumor","enrollment":19},{"nctId":"NCT04876534","phase":"PHASE2","title":"Tocilizumab in Active Moderate-severe Graves' Orbitopathy","status":"UNKNOWN","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2019-12-18","conditions":"Graves Ophthalmopathy","enrollment":64},{"nctId":"NCT02476084","phase":"","title":"Biomarker Signature and Musculoskeletal Ultrasound Profile in Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2014-10-13","conditions":"Rheumatoid Arthritis","enrollment":43},{"nctId":"NCT04227366","phase":"PHASE3","title":"Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Biocad","startDate":"2019-11-19","conditions":"Rheumatoid Arthritis","enrollment":154},{"nctId":"NCT05045001","phase":"","title":"Pharmacogenetic Studies on Anti-IL-6 Receptor Monoclonal Antibodies on the Treatment of Rheumatic Diseases","status":"UNKNOWN","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2021-06-02","conditions":"Rheumatoid Arthritis, Idiopathic Juvenile Arthritis, Giant Cell Arteritis","enrollment":140},{"nctId":"NCT04862377","phase":"PHASE3","title":"Intratracheal Budesonide With Surfactant to Prevent Bronchopulmmonary Dysplasia.","status":"NOT_YET_RECRUITING","sponsor":"Hospital Clinic of Barcelona","startDate":"2021-10-01","conditions":"Bronchopulmonary Dysplasia, Respiratory Distress Syndrome in Premature Infant, Prematurity","enrollment":50},{"nctId":"NCT04927546","phase":"NA","title":"Acute Response to Exercise in Patients With Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2021-08","conditions":"Rheumatoid Arthritis","enrollment":30},{"nctId":"NCT04998253","phase":"EARLY_PHASE1","title":"Effects in Oxygenation and Hypoxic Pulmonary Vasoconstriction in ARDS Secondary to SARS-CoV2","status":"COMPLETED","sponsor":"Unidad Temporal COVID-19 en Centro Citibanamex","startDate":"2020-10-01","conditions":"Hypoxic Pulmonary Vasoconstriction, Hypoxemia, Acute Respiratory Distress Syndrome","enrollment":24},{"nctId":"NCT01696929","phase":"PHASE1","title":"An Open-Label Trial of Tocilizumab in Schizophrenia","status":"COMPLETED","sponsor":"Brian Miller","startDate":"2012-09","conditions":"Schizophrenia","enrollment":8},{"nctId":"NCT04924829","phase":"","title":"Safety and Effectiveness Study of Tocilizumab in Patients With Severe COVID-19","status":"UNKNOWN","sponsor":"Hospital Italiano de Buenos Aires","startDate":"2021-06-01","conditions":"Severe COVID 19 Pneumonia, Tocilizumab","enrollment":300},{"nctId":"NCT03849014","phase":"NA","title":"Comparison of Biochemical Changes in Patients With Trochanteric Region Fracture Fixation With DHS Versus PFN","status":"COMPLETED","sponsor":"Kushtrim Grezda","startDate":"2019-01-01","conditions":"Hip Fractures","enrollment":60},{"nctId":"NCT04762784","phase":"PHASE4","title":"A Prospective Study of Tocilizumab in the Treatment of Idiopathic Retroperitoneal Fibrosis","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-07-01","conditions":"Idiopathic Retroperitoneal Fibrosis","enrollment":40},{"nctId":"NCT04486521","phase":"","title":"Anti-IL6 and Corticosteroid Monotherapy vs Combination in COVID-19","status":"UNKNOWN","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2020-07-22","conditions":"Critical Illness, Corona Virus Infection, Cytokine Release Syndrome","enrollment":860},{"nctId":"NCT03004703","phase":"PHASE2","title":"ASSessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction: The ASSAIL-MI Trial","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2017-03-16","conditions":"Coronary Disease, Myocardial Infarction","enrollment":200},{"nctId":"NCT01624766","phase":"PHASE1","title":"Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-06-19","conditions":"Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm","enrollment":57},{"nctId":"NCT01559103","phase":"PHASE1","title":"Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2012-05-31","conditions":"Rheumatoid Arthritis","enrollment":39},{"nctId":"NCT04740840","phase":"PHASE2, PHASE3","title":"Anti Inflammatory Treatment of Hypertension","status":"COMPLETED","sponsor":"Affiliated Hospital of North Sichuan Medical College","startDate":"2010-05-01","conditions":"Hypertension","enrollment":200},{"nctId":"NCT04690920","phase":"NA","title":"Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 Proteins","status":"COMPLETED","sponsor":"University of Lahore","startDate":"2020-07-23","conditions":"Corona Virus Disease 2019 (COVID-19)","enrollment":200},{"nctId":"NCT04570449","phase":"EARLY_PHASE1","title":"Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)","status":"WITHDRAWN","sponsor":"Milton S. Hershey Medical Center","startDate":"2020-11","conditions":"Covid19","enrollment":""},{"nctId":"NCT04226573","phase":"","title":"Effect of Preoperative Anxiety on Fetus in Pregnant Women","status":"COMPLETED","sponsor":"Bozok University","startDate":"2020-02-01","conditions":"Preoperative Anxiety, Cytokines","enrollment":30},{"nctId":"NCT04322773","phase":"PHASE2","title":"Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure","status":"TERMINATED","sponsor":"Marius Henriksen","startDate":"2020-04-05","conditions":"Corona Virus Disease","enrollment":20},{"nctId":"NCT04115423","phase":"","title":"A Retrospective Cohort Study on the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab","status":"UNKNOWN","sponsor":"Sungkyunkwan University","startDate":"2020-04-01","conditions":"Infection, Rheumatoid Arthritis","enrollment":9508},{"nctId":"NCT03444103","phase":"PHASE2","title":"A Pilot Trial of Clazakizumab in Late ABMR","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2018-01-16","conditions":"Antibody-mediated Rejection","enrollment":20},{"nctId":"NCT02101333","phase":"PHASE3","title":"Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2014-06-10","conditions":"TAKAYASU ARTERITIS","enrollment":18},{"nctId":"NCT04494724","phase":"PHASE2","title":"Clazakizumab vs. Placebo - COVID-19 Infection","status":"UNKNOWN","sponsor":"The Methodist Hospital Research Institute","startDate":"2020-07-13","conditions":"COVID-19 Infection","enrollment":60},{"nctId":"NCT04492501","phase":"NA","title":"Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan","status":"COMPLETED","sponsor":"UNICEF","startDate":"2020-04-01","conditions":"Covid19, Cytokine Release Syndrome, Critical Illness","enrollment":600},{"nctId":"NCT04361552","phase":"PHASE3","title":"Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)","status":"WITHDRAWN","sponsor":"Emory University","startDate":"2020-04-07","conditions":"Cerebrovascular Accident, Chronic Obstructive Pulmonary Disease, Chronic Renal Failure","enrollment":""},{"nctId":"NCT04377750","phase":"PHASE4","title":"The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation","status":"UNKNOWN","sponsor":"Hadassah Medical Organization","startDate":"2020-04-08","conditions":"Covid19 Pneumonia","enrollment":500},{"nctId":"NCT04350216","phase":"PHASE4","title":"Effect of Sarilumab on Atherosclerotic Disease Assessed by PET/CET in Patients With RA (SARIPET)","status":"UNKNOWN","sponsor":"Instituto de Investigación Marqués de Valdecilla","startDate":"2020-04-30","conditions":"Rheumatoid Arthritis, Atherosclerosis","enrollment":20},{"nctId":"NCT04281602","phase":"","title":"Biomarkers in Rheumatoid Arthritis Treated With Anti-interleukin-6 Therapy","status":"UNKNOWN","sponsor":"University Hospital, Caen","startDate":"2020-02-18","conditions":"Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT01484275","phase":"PHASE2","title":"A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-03-01","conditions":"High-risk Smoldering Multiple Myeloma","enrollment":85},{"nctId":"NCT04226430","phase":"","title":"Effect of Cytosorb on Blood Levels of Inflammatory Biomarkers of Sepsis.","status":"COMPLETED","sponsor":"University of Gaziantep","startDate":"2016-06-01","conditions":"Sepsis, Cytokine Storm","enrollment":34},{"nctId":"NCT00046774","phase":"PHASE1","title":"Monoclonal Antibody Treatment for Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","startDate":"2002-09-02","conditions":"Systemic Lupus Erythematosus","enrollment":23},{"nctId":"NCT00401843","phase":"PHASE2","title":"A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2006-11-28","conditions":"Multiple Myeloma","enrollment":307},{"nctId":"NCT02633358","phase":"NA","title":"Anti-inflammatory Effect of Therapeutic Hypothermia in Out-hospital Cardiac Arrest Patients With Cardiogenic Shock","status":"COMPLETED","sponsor":"China Medical University Hospital","startDate":"2015-11-01","conditions":"Cardiac Arrest","enrollment":141},{"nctId":"NCT01284569","phase":"PHASE1, PHASE2","title":"Study to Assess Safety and Efficacy of Anti-Interleukin 6-receptor (IL6R) Nanobody in Rheumatoid Arthritis (RA) Patients","status":"COMPLETED","sponsor":"Ablynx, a Sanofi company","startDate":"2011-03","conditions":"Rheumatoid Arthritis","enrollment":65},{"nctId":"NCT02057770","phase":"PHASE1","title":"Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2014-02-28","conditions":"Leukemia, Myeloid, Acute","enrollment":25},{"nctId":"NCT03194035","phase":"","title":"Inflammation in an Ultra Endurance Race","status":"UNKNOWN","sponsor":"Hôpital Necker-Enfants Malades","startDate":"2018-10-01","conditions":"Inflammation, Inflammatory Response","enrollment":25},{"nctId":"NCT01757197","phase":"PHASE2","title":"Phase II Study of Tocilizumab for Patients With Glucocorticoid-refractory Acute GVHD After Allogeneic Hematopoetic Stem Cell Transplant (HSCT)","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2013-11-07","conditions":"Glucocorticosteroid Refractory Acute GVHD","enrollment":2},{"nctId":"NCT03505411","phase":"NA","title":"The Influence of Melatonin Supplementation in the Group of Persons Performing Competitive Sport.","status":"COMPLETED","sponsor":"Nicolaus Copernicus University","startDate":"2010-01-15","conditions":"Antioxidants, Oxidative Stress, Inflammation","enrollment":81},{"nctId":"NCT01606761","phase":"PHASE3","title":"A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-08-06","conditions":"Arthritis, Rheumatoid","enrollment":878},{"nctId":"NCT01024036","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-03-18","conditions":"Multicentric Castleman's Disease","enrollment":79},{"nctId":"NCT00718718","phase":"PHASE2","title":"A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2008-08-11","conditions":"Arthritis, Rheumatoid","enrollment":187},{"nctId":"NCT01396317","phase":"PHASE2","title":"Study of Tocilizumab to Treat Polymyalgia Rheumatica","status":"COMPLETED","sponsor":"Hospital for Special Surgery, New York","startDate":"2011-04","conditions":"Polymyalgia Rheumatica (PMR)","enrollment":10},{"nctId":"NCT01604343","phase":"PHASE3","title":"A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-08-15","conditions":"Arthritis, Rheumatoid","enrollment":1670},{"nctId":"NCT02765594","phase":"PHASE4","title":"Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2016-06","conditions":"Primary IgA Nephropathy","enrollment":98}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tocilizumab","Sarilumab"],"phase":"phase_1","status":"active","brandName":"Anti-IL6","genericName":"Anti-IL6","companyName":"Marie Hudson, MD","companyId":"marie-hudson-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IL-6 receptor antagonist Used for Rheumatoid arthritis, Multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":5,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}